The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2024 | Sequencing immunotherapies in multiple myeloma
Thomas Martin, MD, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the sequencing of immunotherapies in multiple myeloma (MM). He emphasizes considerations such as bridging therapies, targeting different antigens, and subsequent therapies following disease progression. While acknowledging the current lack of definitive answers, Prof. Martin suggests that real-world experience with these immunotherapies will likely provide insights. This interview took place at The 10th World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Research funding: BMS, Janssen, Sanofi Consultant: Pfizer, GSK
